Related Experiment Video
Updated: Mar 1, 2026
Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility
Published on: April 5, 2024
Advances in the molecular genetics of endometrial cancer (Review)
M Esteller1, J Xercavins, J Reventos
1Centre d'Investigacions en Bioquimica i Biologia Molecular Vall d'Hebron, Hospitals Vall d'Hebron, Barcelona, Spain.
Abstract:
Recent studies have identified some of the genetic alterations involved in endometrial carcinoma development. Transforming genes, including K-ras and c-erbB2/neu oncogenes and the p53, PTEN and hMLH1 tumor suppressor genes, are the most frequently altered. In addition, endometrial carcinomas express high levels of chemoresistance markers, including the MDR-1 or the MRP genes. The genetic background of an endometrial cancer patient may include high-penetrance genes such as the DNA mismatch repair genes causing microsatellite instability, and low-penetrance genes such as those involved in estrogen-metabolism. The spectrum of several molecular lesions suggest a model for endometrial tumorigenesis through two divergent pathways, and which may improve the design of more rational therapeutic agents.
Insights
Genetic alterations in endometrial carcinoma include oncogenes and tumor suppressor genes. Understanding these molecular changes and chemoresistance markers may lead to targeted therapies for endometrial cancer.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Endometrial carcinoma development involves specific genetic alterations.
- Key genes implicated include oncogenes (K-ras, c-erbB2/neu) and tumor suppressors (p53, PTEN, hMLH1).
- Chemoresistance markers like MDR-1 and MRP are highly expressed in these cancers.
Purpose of the Study:
- To summarize the genetic alterations in endometrial carcinoma.
- To discuss the role of genetic background, including high- and low-penetrance genes.
- To propose a model for endometrial tumorigenesis based on molecular lesions.
Main Methods:
- Review of recent studies on genetic alterations in endometrial carcinoma.
- Identification of frequently altered oncogenes and tumor suppressor genes.
- Analysis of chemoresistance markers and their association with cancer development.
Main Results:
- Commonly altered genes in endometrial cancer include K-ras, c-erbB2/neu, p53, PTEN, and hMLH1.
- Endometrial carcinomas exhibit high expression of MDR-1 and MRP genes.
- Genetic factors like DNA mismatch repair genes and estrogen-metabolism genes contribute to patient susceptibility.
- A two-pathway model for endometrial tumorigenesis is suggested by the molecular data.
Conclusions:
- The identified genetic alterations and chemoresistance markers are crucial for understanding endometrial carcinoma.
- The genetic background of patients plays a significant role in disease development.
- A proposed two-pathway model for tumorigenesis may guide the development of targeted therapeutic agents for endometrial cancer.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
